Quito Declaration

IV Meeting of Latin America & Caribbean – Global Alliance for Access to Medicines

DECLARATION

Quito, Ecuador 22 – 24 April 2010

Organizations of the Latin American and Caribbean (LAC) – Global Alliance for Access to Medicines reaffirm their commitment to work to ensure universal access to medicines,

Quito Declaration

DECLARATION

Quito, Ecuador 22 – 24 April 2010

Organizations of the Latin American and Caribbean (LAC) – Global Alliance for Access to Medicines reaffirm their commitment to work to ensure universal access to medicines, in the belief that medicines are enabling factors for the full exercise of the right to life.

EU Ombudsman: Transparency rules apply to all documents held by EMA

In 2008, an Irish citizen asked the European Medicines Agency for access to reports on suspected adverse reactions to a drug used to treat severe forms of acne. The EMA refused this request and the citizen turned to the EU Ombudsman, Mr. P. Nikiforos Diamandouros.

Diamandouros has concluded that:

“Since its work has a direct impact on the health of European citizens,

Patient groups not only for sick people's interests – says Portuguese sociologist

Patient organisations are instrumental to social movements, but they can also be a vehicle for commercial interests, cautions Portuguese sociologist Noemia Lopes of the Instituto Superior de Ciencias de Saude Egas Moniz.

Drawing on several examples from Portugal, Lopes and others cite disclosure policies, donor-recipient interaction guidelines and maintaining a variety of income sources as strategies that could diffuse any dependency on corporate cash.

HAI hosts essay competition for students

Health Action International (HAI) Europe is sponsoring an essay competition open to residents in Europe who are in, or have completed, full-time highereducation in the last eight years. The essay should focus on one of the principle areas of HAI Europe’s policy work:

Rational use of medicines

Access to essential medicines

Democratisation of medicines’ policy

Winning entries will be selected by a panel of referees and announced at the end of June.

EU-India negotiations on FTA pose a serious threat to access to affordable medicines in the developing world

Negotiations on the intellectual property (IP) provisions in the EU–India free trade agreement, of which a round is taking place this week in Brussels, are cause for real concern as they could have a huge impact on Access to Medicines in India and across the developing world.

The EU’s ambitions for IP include provisions on data exclusivity and supplementary protection certificates that would significantly extend the length of the market monopoly for brand pharmaceutical products.

START TYPING AND PRESS ENTER TO SEARCH